Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Sep;8(9):1326-34.
doi: 10.4161/hv.20550. Epub 2012 Aug 16.

Reimbursement challenges with cancer immunotherapeutics

Alex Kudrin  1
Affiliations
Review

Reimbursement challenges with cancer immunotherapeutics

Alex Kudrin. Hum Vaccin Immunother. 2012 Sep.

Abstract

Today the task of cancer vaccine developers is not only to excel in cancer immunology and art of conducting immunotherapy trials but also in the analysis and forecasting the cost-effectiveness of the final product. This article reviews methodology used by EU health-technology bodies in the appraisal of new therapies based on economic and clinical values and different budgetary uncertainties. Increasingly, new oncology treatments were able to access EU market only under provision of risk-sharing agreements with payers and examples of such agreements are given here. Cancer vaccine developers should consider early collection of patient reported outcomes in order to project additional clinical and economic value with immunotherapy. Furthermore, early interaction with different stakeholders including patient organizations, physicians and payer bodies can facilitate market access.

PubMed Disclaimer

Figures

None
Figure 1. Values for reimbursement from payer perspective. (A) measure of clinical value determined with cancer immunotherapy. (B) measures that indicate economic value of a drug.
None
Figure 2. Uncertainties facing payers in assessing product value at launch.
See this image and copyright information in PMC

References

    1. American Cancer Society. (2011) Cancer Facts and Figures 2011. Atlanta, American Cancer Society.
    1. The cancer market outlook to 2016. Business Insights 2011 http://www.researchandmarkets.com/reports/1839878/the_cancer_market_outl...
    1. Desdouits F, Delaporte L, Parnis S. Roadmap for success in oncology. Script 2008 1: 1-11. http://www.researchandmarkets.com/reports/1198415/roadmap_for_success_in...
    1. FDA. (2010) FDA Prescribing Information for Provenge. Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyP... Accessed: April 12, 2012.
    1. Misra G. (2011) Reimbursement in Europe and Indication-Specific Pricing. Business Insights.

Substances

LinkOut - more resources